Physician Wealth Advisors’s Larimar Therapeutics LRMR Stock Holding History

Physician Wealth Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$711	Hold	233	–	–	﹤0.01%	1953
2026 Q1	$1.05K	Hold	233	–	–	﹤0.01%	1657
2025 Q4	$888	Hold	233	–	–	﹤0.01%	1675
2025 Q3	$753	Hold	233	–	–	﹤0.01%	1706
2025 Q2	$674	Buy	+233	New	+$539	﹤0.01%	1624

Other funds holding LRMR

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

NLP

Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Physician Wealth Advisors's LRMR Position: Q2 2026 in Review

Physician Wealth Advisors held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 233 shares worth $711. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Physician Wealth Advisors first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.05K in Q1 2026. 29 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Physician Wealth Advisors held 233 shares of Larimar Therapeutics worth $711 as of Q2 2026.
Physician Wealth Advisors left its Larimar Therapeutics share count unchanged in Q2 2026.
Larimar Therapeutics made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1953 holding.
Physician Wealth Advisors first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
Physician Wealth Advisors's Larimar Therapeutics position peaked at $1.05K in Q1 2026.
29 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.